# Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers

Source: https://onco.cc/trials/nct07162181/  
OnCo record `nct07162181` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Pirtobrutinib in non-hodgkin lymphoma, run by Eli Lilly and Company, active and no longer recruiting.

## Summary

Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers is a phase 2 interventional study registered as NCT07162181 by Eli Lilly and Company, with 13 participants planned, started 2025-08-07 and due to reach its primary completion in 2030-05. Interventions recorded: Pirtobrutinib. Conditions listed: Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, B-cell Lymphoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07162181
- Phase: 2
- Setting: Long-Term Safety of Pirtobrutinib in Participants From Study J2N-MC-JZNJ With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
- Sponsor: Eli Lilly and Company
- Enrolled: 13

## Sources

- ClinicalTrials.gov NCT07162181: https://clinicaltrials.gov/study/NCT07162181

## Connected records

- cancers: [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- drugs: [Pirtobrutinib](https://onco.cc/drugs/pirtobrutinib/)
- companies: [Eli Lilly (incl. Loxo)](https://onco.cc/companies/eli-lilly/)

---
JSON: https://onco.cc/api/v1/entities/nct07162181.json